Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SMAD family member 2 (SMAD2) mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the SMAD2 transcript that governs the stability and translation of the SMAD2 protein (UniProt P67775). SMAD2 is a key intracellular mediator of the transforming growth factor-beta (TGF-beta) signaling pathway, which regulates diverse cellular processes including cell growth, differentiation, and apoptosis (NCBI Gene ID: 4087). The 3' UTR contains binding sites for various microRNAs (miRNAs), such as miR-155 and miR-18a, and RNA-binding proteins (RBPs) that can either promote mRNA degradation or inhibit translation, thereby fine-tuning the levels of SMAD2 protein available for signaling (PubMed: 22393001). Dysregulation of SMAD2 expression, often mediated by alterations in its 3' UTR interactions, is implicated in several diseases, most notably cancer and fibrotic disorders (PubMed: 25666605). In many cancers, loss of SMAD2-mediated growth inhibition or its role in promoting epithelial-mesenchymal transition (EMT) contributes to tumor progression and metastasis. Consequently, the SMAD2 mRNA 3' UTR has emerged as a potential therapeutic target for RNA-based interventions, such as antisense oligonucleotides or miRNA mimics, designed to modulate TGF-beta signaling in a tissue-specific or context-dependent manner (PubMed: 30122545). Targeting this region allows for the modulation of SMAD2 levels without directly inhibiting the TGF-beta receptors, potentially reducing the systemic side effects associated with broad pathway inhibition. Research into small molecules that can bind specific RNA secondary structures within the 3' UTR is also an active area of investigation for therapeutic development.
Modulation of mRNA stability and translation through competitive or complementary binding to regulatory elements within the 3' untranslated region.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SMAD family member 2 (SMAD2) mRNA 3' untranslated region (3' UTR) (SMAD2 mRNA 3' UTR).